summary
Introduced
01/30/2026
01/30/2026
In Committee
01/30/2026
01/30/2026
Crossed Over
Passed
Dead
Introduced Session
2025-2026 Regular Session
Bill Summary
Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for drug overdose medication.
AI Summary
This bill amends The Controlled Substance, Drug, Device and Cosmetic Act to expand the definition of "opioid antagonist," which refers to medications used to reverse opioid overdoses. Specifically, it adds nalmefene hydrochloride and other similarly acting drugs approved by the U.S. Food and Drug Administration (FDA) to the list of recognized opioid antagonists, alongside naloxone hydrochloride. This change aims to broaden the availability of medications that can be used in emergencies to counteract the potentially fatal effects of opioid overdoses.
Committee Categories
Health and Social Services
Sponsors (13)
Chris Pielli (D)*,
Lisa Borowski (D),
Tim Brennan (D),
Johanny Cepeda-Freytiz (D),
Mary Jo Daley (D),
Roni Green (D),
Liz Hanbidge (D),
Carol Hill-Evans (D),
Jeanne McNeill (D),
Brian Munroe (D),
Jenn O'Mara (D),
Ben Sanchez (D),
Dan Williams (D),
Last Action
Referred to Health (on 01/30/2026)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.palegis.us/legislation/bills/2025/hb2181 |
| BillText | https://www.palegis.us/legislation/bills/text/PDF/2025/0/HB2181/PN2835 |
Loading...